Amadeus Capital is a global technology investor that invests in technology companies at all stages, from seed to venture buyout; they also buy stakes from other investors or founders, to ensure that companies and entrepreneurs have the runway they need to succeed. They invest in a broad variety of sectors including enterprise and infrastructure software, consumer and business services, medical technology and healthcare IT, and cleantech and resource efficiency. It has the imagination to see where new businesses can be created and the technical insight, operational experience and global network to help entrepreneurs make their vision a reality. The Company was founded in 1997 and since has backed more than 130 companies and raised over $1bn for investment.

Amadeus Capital Partners

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK. Typical funding requirements that the Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds. Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Cambridge Angels group

Campden Hill Capital is an advisor to a single-family office in the UK that engages in venture capital activities.

Campden Hill Capital

Balderton Capital is a Venture Capital Investor that supports technology businesses. They support Founders at every stage of their journey. They provide advice, introduce portfolio leaders to professional service providers, and invite portfolio leaders to workshops and community events where they can meet one another.

Balderton Capital

Trend Investment Group is a private equity firm. Trend Investment Group focuses on seed-stage, early-stage, and later-stage healthcare and technology firms.

Trend Investment Group

Ruttenberg Gordon Investments (“RGI”) specializes in equity and debt investments in real estate, private equity, growth equity, and alternative hard assets. To date the firm has made 100+ investments amounting to $3Bn+ of total transaction volume.

Ruttenberg Gordon Investments

Atomico is an international investment firm that focuses on helping disruptive technology companies scale globally. It partners with technology founders at the Seed stage and beyond with a particular focus on Europe, leveraging deep operational experience to supercharge their growth. The company's team of founders, investors, and operational leaders have been responsible for global expansion, hiring, and marketing at companies from Skype, Google, and Twitter to Wise and Snowflake. It specializes in seed, startup, Series A, early venture, mid venture, late venture, emerging growth, and growth capital investments.   Atomico was founded in 2006 and is headquartered in London, England, with offices in Paris, Berlin, and Stockholm

Atomico

Intel Capital invests in innovative startups targeting cloud and AI infrastructure, edge, 5G, autonomy, cybersecurity, client & gaming, enterprise applications, silicon design and manufacturing, and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US$12.9 billion in more than 1,582 companies worldwide. Intel Capital has adopted the Diversity Term Sheet Rider.

Intel Capital

Global Brain Corporation is a venture capital firm that invests in companies from seed or early to pre-IPO startups.  Global Brain has invested in 300+ startups from seed/early to pre-IPO startups and achieved 25 IPOs and 61 M&As as a result of providing hands-on support services and resources to its portfolio startups. Global Brain has managed a pure investment fund as well as multiple corporate venture capital funds partnered together with tier 1 public companies of telecom, real estate development, financial service, beverages, agriculture food, logistics, and electronic devices.

Global Brain Corporation

B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.

b2venture

R42 Group actively invents and finances deep science ventures. R42 Group will work from the pre-seed inventing stage through to the growth stage.

R42 Group

Investment firm which in backing biotech, offering investors the opportunity to back promising medical innovations via the EIS and  SEIS.

O2h Ventures

Propel(x) is an angel investing platform focused on funding early-stage companies that are built around scientific discovery.  The company is driven by a mission to help propel mankind by enabling investments in technologies that matter.  Propel(x) was founded in 2014 and is headquartered in San Francisco, California.

Propel(X)

VU Venture Partners is a multi-stage venture capital fund focusing on Consumer, Enterprise, FinTech / Blockchain, HealthTech, Frontier Tech, and Real Estate Tech. It was founded in 2018 and is based in San Francisco, California.

VU Venture Partners

Ayana Capital invests in Pre-seed through Series A rounds and aim to create strong ties and meaningful synergies.

Ayana capital

Healx

Healx is a rare disease biotechnology company that uses generative AI for drug discovery. Healx utilizes advanced artificial intelligence (AI) and machine learning technologies to identify potential drug candidates and repurpose existing drugs for new therapeutic applications. By focusing on drug repurposing, Healx aims to find new uses for existing medications, leveraging their known safety profiles and reducing the risk and cost associated with developing new drugs from scratch.

UK-based Healx focuses on repurposing drugs for rare diseases by leveraging its AI platform Healnet, which uses natural language processing (NLP) to extract disease knowledge from published and proprietary data. Healx claims it can predict new treatments in three months and advance the drug to the clinical stage in 24 months. The company has also been working with various patient groups to collect data to be used for its AI software.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Healx’s $47m Series C Funding Round

Sanofi

To ascertain new disease indications for a Sanofi compound that was previously discontinued using Healx’s advanced AI-driven drug discovery platform, Healnet.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

UK-based Healx focuses on repurposing drugs for rare diseases by leveraging its AI platform Healnet, which uses natural language processing (NLP) to extract disease knowledge from published and proprietary data. Healx claims it can predict new treatments in three months and advance the drug to the clinical stage in 24 months. The company has also been working with various patient groups to collect data to be used for its AI software.The company has 16 active projects, three of which are about to enter Phase I clinical trials. Its pipeline consists of drug candidates targeting rare neuro-developmental diseases, rare oncology diseases, and rare metabolic diseases. It also claims its mission is to progress 50 rare disease therapies to the clinic by 2025.Key customers and partnershipsHealx has partnerships with the German pharmaceutical company Boehringer Ingelheim, the Children’s Tumor Foundation (CTF), and the Foundation for Angelman Syndrome Therapeutics. In <a href="https://sp-edge.com/updates/4786">August 2021 </a>, it partnered with Ono Therapeutics to jointly identify new disease indications with high unmet needs.

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
 Healx, a UK biotech firm utilizing AI, has joined forces with Sanofi to investigate the potential of an inactive Sanofi compound. The collaboration's goal is to determine new disease applications for a previously stopped Sanofi compound using Healx's sophisticated AI drug discovery platform, Healnet. This approach is designed to prevent any beneficial compound from being wasted, particularly in relation to rare illnesses that currently don't have treatment methods.
 
</div> Analyst QuickTake : 
 The Healnet platform was previously employed in a similar drug discovery collaboration in <a href="https: 
//sp-edge.com/updates/4786"> August 2021 </a> with the Japanese pharmaceutical company Ono Pharmaceuticals to use the platform to find novel therapeutic indications for Ono’s proprietary assets. The partnership aimed to allow Healx to expand its drug discovery capabilities from common to rare and unmet disease indications.&nbsp;

Healx

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless